Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Director/PDMR Shareholding and Additional Listing

20 Oct 2008 07:00

RNS Number : 1671G
Synairgen plc
20 October 2008
 



20 October 2008

Director dealings

Synairgen plc ("Synairgen" or the "Company") was notified on 17 October that on the same day John Ward, Finance Director, acquired 22,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at 22 pence per share, equating to 0.01 per cent of the Company's issued Ordinary Share capital. Following this acquisition, Mr Ward has a beneficial interest of 44,692 Ordinary Shares, equating to 0.21 per cent of the Company's issued Ordinary Share capital. 

The Company was also notified on 17 October that on the same day Simon Shaw, non-executive chairman, exercised 700,000 of his Founder Options at nominal value. Following this exercise, Mr Shaw has a beneficial interest of 805,400 Ordinary Shares, equating to 3.71 per cent of the Company's issued share capital.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 700,000 Ordinary Shares (the "New Ordinary Shares"). The New Ordinary Shares are being admitted pursuant to the exercise of options under the Synairgen Chairman's 2004 New Share Option Agreement. It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 24 October 2008.

For further information:

Synairgen plc

John Ward

+44 2380 512800

Teathers Limited

Shaun Dobson/Claes Spang

+44 20 7426 9000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFKOKNABDDOKD
Date   Source Headline
9th Apr 20257:00 amRNSCancellation - Synairgen plc
3rd Apr 20257:00 amRNSUpdate on trading post cancellation
28th Mar 20252:21 pmRNSResult of General Meeting
11th Mar 20257:00 amRNSProposed cancellation of trading on AIM
17th Jan 202512:55 pmRNSHolding(s) in Company
16th Jan 20253:42 pmRNSMartin Murphy appointed as Non-Executive Director
16th Jan 20253:42 pmRNSResult of General Meeting and Total Voting Rights
15th Jan 20255:37 pmRNS£18m raised to fund Phase 2 INVENT clinical trial
20th Dec 20247:00 amRNSProposed Fundraising
30th Oct 20246:09 pmRNSExercise of Share Options and Total Voting Rights
10th Oct 20245:05 pmRNSResults of AGM and Appointment of New Chairman
26th Sep 20247:00 amRNSInterim Results
18th Sep 20247:00 amRNSAppointment of New Chairman and Notice of AGM
5th Sep 20247:00 amRNSBoard Change
27th Jun 20247:00 amRNS2023 Full Year Results
15th Nov 20237:00 amRNSGrant of Options
11th Oct 20237:00 amRNSAppointment of New Chief Financial Officer
3rd Oct 20237:00 amRNSAppointment of Chief Medical Officer
21st Sep 20237:00 amRNSInterim Results
29th Jun 20236:02 pmRNSResult of AGM
29th Jun 202310:00 amRNSAnnual General Meeting Presentation
22nd Jun 20237:00 amRNSGrant of Options
23rd May 20237:00 amRNSPosting of Annual Report and Notice of AGM
27th Apr 20237:00 amRNS2022 Full Year Results
17th Apr 20237:00 amRNSNotice of Full Year results
13th Mar 20234:40 pmRNSSecond Price Monitoring Extn
13th Mar 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 202211:30 amRNSSPRINTER Trial Results Published
14th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSBoard Changes
7th Nov 20224:40 pmRNSSecond Price Monitoring Extn
7th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
3rd Nov 20224:35 pmRNSPrice Monitoring Extension
20th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20221:35 pmRNSHolding(s) in Company
4th Oct 20227:02 amRNSData from the US NIH-led ACTIV-2 Phase 2 trial
29th Sep 20227:01 amRNSBoard Changes
29th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSSPRINTER Long COVID data presented at IDWeek
15th Sep 20227:00 amRNSNotice of Interim Results
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSPositive Findings from SG015 Tri-al Analysis
5th Sep 20227:00 amRNSCompany Announce Collaboration on UNIVERSAL Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.